A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931.

Journal Article (Clinical Trial;Journal Article)

A quality of life (QOL) endpoint supplemented standard clinical endpoints of survival, tumor response, and toxicity in a double-blind study conducted by the Cancer and Leukemia Group B (CALGB) where 291 patients with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive cisplatin/vinblastine with either hydrazine sulfate (HS) or placebo. The difficulties associated with the analysis of the longitudinal QOL data, and the contributions that the QOL endpoint made to the understanding of treatment differences, will be the focus of this paper.

Full Text

Duke Authors

Cited Authors

  • Herndon, JE; Fleishman, S; Kosty, MP; Green, MR

Published Date

  • August 1997

Published In

Volume / Issue

  • 18 / 4

Start / End Page

  • 286 - 300

PubMed ID

  • 9257067

International Standard Serial Number (ISSN)

  • 0197-2456

Digital Object Identifier (DOI)

  • 10.1016/0197-2456(96)00116-x


  • eng

Conference Location

  • United States